CHF5074: Phase IIa data

A double-blind, placebo-controlled, dose-ranging Phase IIa trial in 96 patients with mild cognitive impairment (MCI) showed that once-daily oral CHF5074 for 12 weeks was well tolerated with a MTD of 6...